Study subjects’ responses to placebo have increased from an average two-point decline in symptom ratings in studies done from 1991 to 1998, to an average decline of 7 points in studies done between 1999 and 2008.
Related item:
FDA tracks rising impact of the ‘placebo effect’ in antipsychotic trials